Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Tamás Henics is active.

Publication


Featured researches published by Tamás Henics.


Infection and Immunity | 2003

Functional Selection of Vaccine Candidate Peptides from Staphylococcus aureus Whole-Genome Expression Libraries In Vitro

Thomas Weichhart; Markus Horky; Johannes Söllner; Susanne Gangl; Tamás Henics; Eszter Nagy; Andreas Meinke; Alexander von Gabain; Claire M. Fraser; Steve R. Gill; Martin Hafner; Uwe von Ahsen

ABSTRACT An in vitro protein selection method, ribosome display, has been applied to comprehensively identify and map the immunologically relevant proteins of the human pathogen Staphylococcus aureus. A library built up from genomic fragments of the virulent S. aureus COL strain (methicillin-resistant S. aureus) allowed us to screen all possible encoded peptides for immunoreactivity. As selective agents, human sera exhibiting a high antibody titer and opsonic activity against S. aureus were used, since these antibodies indicate the in vivo expression and immunoreactivity of the corresponding proteins. Identified clones cluster in distinct regions of 75 genes, most of them classifiable as secreted or surface-localized proteins, including previously identified virulence factors. In addition, 14 putative novel short open reading frames were identified and their immunoreactivity and in vivo mRNA expression were confirmed, underscoring the annotation-independent, true genomic nature of our approach. Evidence is provided that a large fraction of the identified peptides cannot be expressed in an in vivo-based surface display system. Thus, in vitro protein selection, not biased by the context of living entities, allows screening of genomic expression libraries with a large number of different ligands simultaneously. It is a powerful approach for fingerprinting the repertoire of immune reactive proteins serving as target candidates for active and passive vaccination against pathogens.


Vaccine | 2010

Immunological fingerprinting of group B streptococci: from circulating human antibodies to protective antigens.

Andreas Meinke; Beatrice Senn; Zehra Visram; Tamás Henics; Duc Bui Minh; Wolfgang Schüler; Christina Neubauer; Dieter Gelbmann; Birgit Noiges; Jan Sinzinger; Markus Hanner; Shailesh Dewasthaly; Urban Lundberg; Knut Hordnes; Helga Masoud; Paul Sevelda; Alexander von Gabain; Eszter Nagy

Group B streptococcus is one of the most important pathogens in neonates, and causes invasive infections in non-pregnant adults with underlying diseases. Applying a genomic approach that relies on human antibodies we identified antigenic GBS proteins, among them most of the previously published protective antigens. In vitro analyses allowed the selection of conserved candidate antigens that were further evaluated in murine lethal sepsis models using several GBS strains. In active and passive immunization models, we identified four protective GBS antigens, FbsA and BibA, as well as two hypothetical proteins, all shown to contribute to virulence based on gene deletion mutants. These protective antigens have the potential to be components of novel vaccines or targets for passive immune prophylaxis against GBS disease.


Vaccine | 2009

Composition of the ANTIGENome of Helicobacter pylori defined by human serum antibodies

Andreas Meinke; Martin Storm; Tamás Henics; Dieter Gelbmann; Sonja Prustomersky; Zoltán Kovács; Duc Bui Minh; Birgit Noiges; Ulrike Stierschneider; Manfred Berger; Alexander von Gabain; Lars Engstrand; Eszter Nagy

Helicobacter pylori is the most prevalent human pathogen and although, it remains silent in most individuals for lifetime, colonization may develop into severe gastric and duodenal conditions. Rapidly developing resistance to antibiotic treatment urgently calls for the development of effective vaccines. We determined the ANTIGENome of two clinical isolates of H. pylori, KTH-Ca1 and KTH-Du, derived from patients with gastric cancer and duodenal ulcer, respectively. Using disease-relevant human sera from well-characterized donors we identified 124 annotated ORFs and 54 non-annotated peptides as antigens. Through in vitro validation assays we selected the 20 most promising vaccine candidates. Importantly, two candidates represent proteins that were previously shown to provide protection in models of H. pylori infection. One of the most frequently selected and conserved protein, the siderophore-dependent transporter HP1341, was confirmed to show high reactivity with human serum IgGs. These analyses provide the means to identify novel antigens for the selection of vaccine candidates, as well as disease associated biomarkers.


Cell Biology International | 2006

RNA delivery by heat shock protein-70 into mammalian cells: a preliminary study.

Tamás Henics; Christine Zimmer

Heat shock proteins (Hsps) are ubiquitous molecular chaperones with indispensable roles in assisting protein folding and giving protection from proteotoxic environmental harm. Members of the 70‐kDa heat shock protein family have been demonstrated to recognize and bind with distinguished RNA sequences, which function as determinants of eukaryotic mRNA stability. We have earlier identified the molecular domains involved in RNA‐binding and characterized in detail the specificity, affinity and some regulatory aspects of this molecular interaction using various deletion mutants and homologues of Hsp70. We have shown that wild type, but not any of the tested truncated mutants of Hsp70, is efficiently taken up by P388 mouse macrophage cells. Here we addressed the question of whether Hsp70 is capable of delivering bound RNA into mammalian cells. Employing fluorescence and confocal microscopy, we demonstrated that full length Hsp70 facilitates the uptake of RNA molecules into the cytoplasm of mammalian cells. We propose that further optimization of this system might enable the development of a valuable tool to deliver RNA molecules, such as siRNA, dsRNA or other regulatory RNA sequences to probe or influence various regulatory processes in eukaryotic cells.


Archive | 2002

A method for identification, isolation and production of antigens to a specific pathogen

Andreas Meinke; Eszter Nagy; Ahsen Uwe Von; Christoph Klade; Tamás Henics; Wolfgang Zauner; Duc Bui Minh; Oresta Vytvytska; Hildegard Etz; Agnieszka Dryla; Thomas Weichhart; Martin Hafner; Brigitte Tempelmaier; Claire M. Fraser; Steven Gill


Vaccine | 2005

Antigenome technology : a novel approach for the selection of bacterial vaccine candidate antigens

Andreas Meinke; Tamás Henics; Markus Hanner; Duc Bui Minh; Eszter Nagy


BioTechniques | 2003

Small-fragment genomic libraries for the display of putative epitopes from clinically significant pathogens

Tamás Henics; Birgit Winkler; U. Pfeifer; Steven R. Gill; Michael Buschle; A. von Gabain; Andreas Meinke


Current Opinion in Microbiology | 2004

Bacterial genomes pave the way to novel vaccines

Andreas Meinke; Tamás Henics; Eszter Nagy


Archive | 2004

H pylori antigens

Andreas Meinke; Du Min Bui; Eszter Nagy; Tamás Henics


Archive | 2005

Identification of the ‘Antigenome’ — A Novel Tool for Design and Development of Subunit Vaccines against Bacterial Pathogens

Eszter Nagy; Tamás Henics; Alexander von Gabain; Andreas Meinke

Collaboration


Dive into the Tamás Henics's collaboration.

Researchain Logo
Decentralizing Knowledge